![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/5944/TOC-Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})
Declaration of interest
DJ Nutt is Chair of the charity Drug Science. M Lynskey is Chief Research Officer of Drug Science. AK Schlag is Acting CEO and Head of Research of Drug Science. She is also scientific advisor to Evolve and Somai. Drug Science receives an unrestricted educational grant from a consortium of medical cannabis companies to further its mission, that is the pursuit of an unbiased and scientific assessment of drugs regardless of their regulatory class. All Drug Science committee members, including the Chair, are unpaid by Drug Science for their effort and commitment to this organization. None of the authors would benefit from the wider prescription of medical cannabis in any form. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.
Acknowledgments
We thank all T21 patients who are continuing to provide their date to develop the scientific evidence based on medical cannabis. We would like to express gratitude to our partners whose generosity is enabling T21 patients to received their CBMPs at a reduced rate: Somai Pharmaceuticals, Blackpoint Biotech, Ethypharm and 4CLabs. We also thank our previous partners Alta Flora, Cellen Biotech LtD., JMCC Group, Khiron Life Sciences Corp., and Lyphe Group.
Reviewer disclosures
A reviewer on this manuscript has disclosed that previously they served as an expert advisor for several licensed producers of medical cannabis in Canada and maintain a Pro bono association with Empower Pharma a company that will produce CBD tablets. Peer reviewers on this manuscript have no other relevant financial relationships or otherwise to disclose.